Form 4: Guardant Health Executive Chris Freeman Reports Stock Transactions
SEC Form 4 Filing
Chris Freeman, Chief Commercial Officer of Guardant Health, reports the vesting of performance-based restricted stock units and associated tax withholding.
Summary
- On March 1, 2025, Chris Freeman, the Chief Commercial Officer of Guardant Health, Inc., reported transactions involving the company's common stock and performance-based restricted stock units.
- Freeman acquired 5,686 shares of common stock upon the vesting of performance-based restricted stock units.
- 1,566 shares were withheld by the company to cover tax obligations related to the vesting of the restricted stock units at a price of $42.55.
- Following these transactions, Freeman directly owns 38,789 shares of Guardant Health common stock and 11,376 performance-based restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions, and the sentiment is neutral.
Future Outlook
The remaining 67% of the performance-based restricted stock units will vest over the following two years, with 33% vesting on January 1, 2026, and 34% vesting on January 1, 2027.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies. It provides transparency into the executive's holdings and aligns their interests with those of the shareholders.
Stakeholder Impact
- The stock transactions have a minor impact on shareholders as they reflect the executive's compensation and alignment with company performance.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of grant for performance-based restricted stock unit award |
| 03/01/2025 | Date of stock transactions (vesting and tax withholding) |
| 03/04/2025 | Date of Form 4 filing |
| 01/01/2026 | Next vesting date for 33% of remaining shares subject to the performance-based restricted stock unit award |
| 01/01/2027 | Final vesting date for 34% of remaining shares subject to the performance-based restricted stock unit award |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.